Accessibility Menu
Bristol Myers Squibb logo

Bristol Myers Squibb(NYSE) BMY

Market Cap$133.37BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1968)+21,995%
5 Year+18%
1 Year+58%
1 Month+17%
$65.43
+0.88%
+0.57Today
After hours$65.48+$0.05 (+0.08%)
Bristol Myers Squibb last closing stock price
MetricPriceDate
Last closeUSD 65.312026-07-31
Bristol Myers Squibb stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.19%USD 62.092026-07-24
1 month+17.02%USD 55.812026-07-01
3 month+13.44%USD 57.572026-05-01
Year to date+25.17%USD 52.182025-12-31
1 year+58.03%USD 41.332025-07-31
3 year+22.24%USD 53.432023-08-01
5 year+18.1%USD 55.302021-07-30
Since inception+21,994.97%USD 0.301968-01-02

Bristol Myers Squibb Financials at a Glance

Market Cap

$133.37BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$49.19B

Net Income (TTM)

$9.28B

EPS (TTM)

$4.54

P/E Ratio

14.39

Dividend

$2.51

Beta (Volatility)

0.29 (Low)

Price

$65.43

Volume

14,580,254

Open

$65.00

Previous Close

$65.31

Daily Range

$63.53 - $65.66

52-Week Range

$42.52 - $65.66

Estimated Earnings Date

Oct 29, 2026

BMY News

23_11_13 A scientist working with a flask and beaker _GettyImages-1413606015-1201x633-65d4be6

Bristol Myers Squibb Isn't Nearly as Cheap as It Looks -- Here's the 1 Thing That Could Change That

Reuben Gregg BrewerAug 1, 2026
Person giving the thumbs up after receiving a vaccination shot

Why Bristol Myers Squibb Stock Topped the Market on Thursday

Eric VolkmanJul 30, 2026
Bristol Myers Squibb logo

This Healthcare Leader Just Made a Bet on Artificial Intelligence (AI): Time to Buy the Stock?

Prosper Junior BakinyJul 28, 2026
Israel Englander_Millennium Management_Founder & CEO_imageSource_Getty Images

Israel "Izzy" Englander Increased His Position in This Pharma Stock by 780%. Does He Know Something Wall Street Doesn't?

Keith SpeightsJul 26, 2026
Dividend yield suitcase clock

Is Bristol Myers Squibb's Dividend Too Good to Be True? Here's My Honest Answer

Justin PopeJul 24, 2026
A biotech lab technician using multiple pipettes to load blood samples into test tubes.

5 Best Biotech Stocks for 2026 and How to Invest

Keith SpeightsJul 17, 2026
office_building_commercial_real_estate

5 Best Commercial Real Estate Stocks for 2026

Kristi WaterworthJul 16, 2026
Woman question marks in background

Is Bristol Myers Squibb's 4.3% Dividend Yield Safe? Here's What Investors Need to Know.

Keith SpeightsJul 6, 2026
Page 1

BMY: Motley Fool Moneyball Superscore

66

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bristol Myers Squibb

Bristol-Myers Squibb makes medicines for cancer, heart, and immune diseases. Its drugs help patients manage serious health conditions. Products like Eliquis are used for stroke prevention and Opdivo is used for cancer treatment.

Pill Bottles and Beyond: What Bristol-Myers Squibb Sells

  • Oncology and Hematology: Cancer and blood disorder drugs, including Opdivo, Revlimid, and Pomalyst, for hospitals and clinics.
  • Cardiovascular (Eliquis, about 28% of revenue in 2024): Eliquis helps prevent strokes and blood clots in patients with heart rhythm disorders.
  • Immunology: Orencia and Zeposia treat autoimmune diseases like rheumatoid arthritis and multiple sclerosis for adults.
  • Cell Therapies: Breyanzi and Abecma are advanced treatments for certain blood cancers, used when other options fail.
  • Neuroscience: Cobenfy, launched in 2024, addresses schizophrenia symptoms for adult patients.

Growth Spurts: How Bristol-Myers Squibb Got Bigger

  • Acquired Karuna (neuroscience), RayzeBio (radiopharmaceuticals), and Mirati (oncology) in 2024.
  • Launched new drugs in 2024, including Cobenfy for schizophrenia and Krazati for certain cancers.
  • Expanded manufacturing and research sites in the US, India, and Europe in 2024.
  • Formed strategic alliances, such as with Pfizer for Eliquis and SystImmune for new cancer therapies.

What Makes Bristol-Myers Squibb Stand Out

The company distributes medicines globally, reaching hospitals, pharmacies, and clinics. It invests heavily in research, focusing on new treatments for hard-to-treat diseases. Strategic acquisitions and partnerships help Bristol-Myers Squibb diversify its product pipeline and expand into new markets.

Five Things You Need to Know

  • Total revenue was $48.3 billion in 2024, up 7% from 2023.
  • US sales made up 71% of revenue in 2024; international sales were 27%.
  • R&D expenses rose 20% to $11.2 billion in 2024.
  • Net loss was $8.95 billion in 2024, mainly due to acquisition costs.

Bottom Line

Bristol-Myers Squibb has evolved through acquisitions, new drug launches, and global expansion. Its focus on research and diverse products helps it adapt in a changing healthcare market.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

32,500

CEO

Christopher S. Boerner, PhD, MBA

Website

www.bms.com

Headquarters

Princeton, NJ 08543, US

BMY Financials

Key Financial Metrics (TTM)

Gross Margin

70.16%

Operating Margin

28.27%

Net Income Margin

18.87%

Return on Equity

46.75%

Return on Capital

20.92%

Return on Assets

10.59%

Earnings Yield

6.95%

Dividend Yield

3.84%

Payout Ratio

54.89%

Stock Overview

Market Cap

$133.37BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.04B

Volume

14.58M

Avg. Volume

11.92M

Financials (TTM)

Gross Profit

$34.51B

Operating Income

$13.90B

EBITDA

$16.67B

Operating Cash Flow

$12.78B

Capital Expenditure

-$1.34B

Free Cash Flow

$11.44B

Cash & ST Invst.

$11.07B

Total Debt

$43.12B

Bristol Myers Squibb Performance Analysis

Bristol Myers Squibb annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 46,159,000,000-0.5%
20232023-12-31USD 45,006,000,000-2.5%
20242024-12-31USD 48,300,000,0007.3%
20252025-12-31USD 48,194,000,000-0.2%
Bristol Myers Squibb sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-0.4%
Q42025-12-312.3%
Q12026-03-31-8.1%
Q22026-06-3012.9%
Bristol Myers Squibb annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 2.95-5.4%
20232023-12-31USD 3.8631.0%
20242024-12-31USD -4.41N/A
20252025-12-31USD 3.46N/A
Bristol Myers Squibb sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3068.8%
Q42025-12-31-50.9%
Q12026-03-31147.2%
Q22026-06-3023.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$12.97B

+5.7%

Gross Profit

$9.25B

+3.9%

Gross Margin

71.28%

N/A

Market Cap

$133.37BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.10M

N/A

Employees

32,500

N/A

Net Income

$3.32B

+153.2%

EBITDA

$4.94B

+51.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$11.07B

-18.6%

Total Debt

$43.12B

-15.3%

Accounts Receivable

$10.55B

-30.1%

Inventory

$2.74B

+0.0%

Long Term Debt

$42.09B

-8.5%

Short Term Debt

$1.03B

-79.1%

Return on Assets

10.59%

N/A

Return on Invested Capital

20.16%

N/A

Free Cash Flow

$3.09B

-13.2%

Operating Cash Flow

$3.39B

-13.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CVSCVS Health Corp.
$104.43-0.75%
PFEPfizer Inc.
$25.01+0.40%
VRTXVertex Pharmaceuticals Incorporated
$477.10-0.95%
GSKGSK plc
$51.69-0.73%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About BMY

What is the current price of Bristol Myers Squibb?

Bristol Myers Squibb is trading at $65.31 per share.

What is the 52-week range for Bristol Myers Squibb?

Over the past 52 weeks, Bristol Myers Squibb has traded between $42.52 and $65.66.

How much debt does Bristol Myers Squibb have?

As of the most recent reporting period, Bristol Myers Squibb reported total debt of $45.05B.

How much cash does Bristol Myers Squibb have on hand?

Bristol Myers Squibb reported $8.72B in cash and cash equivalents in its most recent financial results.

What is Bristol Myers Squibb’s dividend yield?

Bristol Myers Squibb currently has a dividend yield of 3.84%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services